Meloxicam Basi (Meloxicam)

Meloxicam selectively blocks the cyclooxygenase‑2 (COX‑2) enzyme, which is responsible for producing prostaglandins that promote inflammation, pain, and fever. By lowering prostaglandin levels, meloxicam diminishes these symptoms while preserving COX‑1 activity that protects the stomach lining.

The appropriate dose of Meloxicam Basi is determined by the prescribing healthcare professional based on the patient’s condition, severity, and individual response. Dosage adjustments may be needed for renal or hepatic impairment, and the prescriber will provide specific instructions.

Safety data for meloxicam in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Meloxicam offers a relatively selective COX‑2 inhibition, which may result in a lower incidence of gastrointestinal side effects compared with non‑selective NSAIDs like ibuprofen or diclofenac. However, cardiovascular and renal risks remain, and choice of therapy should be individualized.

Meloxicam Basi should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, heat, and direct sunlight to maintain stability and potency.

Meloxicam Basi is taken orally, usually with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

Serious risks include gastrointestinal bleeding or ulceration, cardiovascular events such as heart attack or stroke, severe renal impairment, and rare but life‑threatening hypersensitivity reactions like Stevens‑Johnson syndrome. Patients should be monitored for these events, especially if risk factors exist.

Meloxicam Basi is contraindicated in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active peptic ulcer disease, severe heart failure, or significant renal or hepatic impairment. It should also be avoided in patients who have had a recent myocardial infarction.